Loading...
•
Dec 31, 2020
Edwards Lifesciences Q4 2020 Earnings Report
Edwards Lifesciences reported fourth quarter results with sales increasing 1 percent and adjusted EPS growing 2 percent.
Key Takeaways
Edwards Lifesciences reported Q4 sales increased 1 percent to $1.2 billion, with underlying sales flat. The company's Q4 EPS was $0.49, and adjusted EPS grew 2 percent to $0.50. The company reiterated its 2021 guidance with sales growth expected in the mid-teens.
Q4 sales increased 1 percent to $1.2 billion; underlying sales flat
Q4 TAVR sales grew 2 percent; underlying sales flat
Q4 EPS was $0.49; adjusted EPS grew 2 percent to $0.50
December investor conference highlighted 2021 and long-term outlook
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Overall, full year 2021 sales guidance for Edwards remains $4.9 to $5.3 billion. Additionally, the company continues to expect full year 2021 adjusted earnings per share of $2.00 to $2.20. For the first quarter of 2021, the company projects total sales to be between $1.1 and $1.2 billion, and adjusted EPS of $0.43 to $0.50.
Positive Outlook
- Full year 2021 sales guidance remains $4.9 to $5.3 billion.
- Full year 2021 adjusted earnings per share expected to be $2.00 to $2.20.
- First quarter of 2021 total sales projected to be between $1.1 and $1.2 billion.
- First quarter 2021 adjusted EPS projected to be $0.43 to $0.50.
- Continuing to invest in innovations to enhance patients’ lives.
Challenges Ahead
- Expect a COVID impact on sales in the start of the year.
- Uncertain impact and timeframe for recovery from the global challenge.
- COVID had a more pronounced impact on the company’s U.S. sales, which declined mid-single digits
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...